Zhao Yufei, Wang Zhiwei, Kuang Shangke, Zhang Shuxin
Department of Anorectal, Beijing University of Chinese Medicine, Beijing, China.
Department of Anorectal, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Front Med (Lausanne). 2025 Aug 20;12:1592220. doi: 10.3389/fmed.2025.1592220. eCollection 2025.
To evaluate the efficacy and safety of acupoint embedding for FC by meta-analysis, in order to provide evidence-based medical evidence for clinical practice.
A comprehensive literature search was conducted in China National Knowledge Infrastructure, WanFang, VIP, PubMed, Web of Science and The Cochrane Library for randomised controlled trials (RCTs) on ACE for FC published from inception to November 2024. The included studies were assessed for quality using the modified Jadad scale, and statistical analysis was performed using RevMan 5.4.1 and Stata BE 17.
A total of 23 studies involving 1,794 patients were included. The meta-analysis showed that the total effective rate of ACE was significantly higher compared with oral Western medicine (odds ratio [OR] = 2.71, 95% confidence interval [CI]: 1.91-3.83, < 0.00001), acupuncture (OR = 2.90, 95% CI: 1.68-5.01, = 0.0001) and placebo groups ( < 0.05). There was no significant difference between ACE and oral Chinese medicine (OR = 2.34, 95% CI: 0.79-6.89, = 0.12). The incidence of adverse reactions in the ACE group was low, presenting mainly as mild local discomfort such as soreness, bruising and pain, which were self-limiting.
Acupoint catgut embedding demonstrates superior clinical efficacy compared with Western medicine, acupuncture and placebo in treating FC, with a low incidence of adverse effects. However, due to the limitations of the included studies, high-quality, large-sample RCTs are still needed to verify the long-term efficacy and safety of ACE.
Identifier INPLASY202570017.
通过荟萃分析评估穴位埋线治疗功能性便秘(FC)的疗效和安全性,为临床实践提供循证医学依据。
在中国知网、万方、维普、PubMed、Web of Science和考克兰图书馆全面检索从创刊至2024年11月发表的关于穴位埋线治疗FC的随机对照试验(RCT)。采用改良Jadad量表对纳入研究进行质量评估,并使用RevMan 5.4.1和Stata BE 17进行统计分析。
共纳入23项研究,涉及1794例患者。荟萃分析显示,穴位埋线的总有效率显著高于口服西药(比值比[OR]=2.71,95%置信区间[CI]:1.91 - 3.83,P<0.00001)、针刺(OR = 2.90,95% CI:1.68 - 5.01,P = 0.0001)和安慰剂组(P<0.05)。穴位埋线与口服中药之间无显著差异(OR = 2.34,95% CI:0.79 - 6.89,P = 0.12)。穴位埋线组不良反应发生率较低,主要表现为轻度局部不适,如酸痛、瘀斑和疼痛,均为自限性。
与西药、针刺和安慰剂相比,穴位埋线治疗FC具有更好的临床疗效,不良反应发生率低。然而,由于纳入研究的局限性,仍需要高质量、大样本的RCT来验证穴位埋线的长期疗效和安全性。
标识符INPLASY202570017。